Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Multiple Myeloma 307 Recurrence 64 Neoplasms 32 Neoplasms, Plasma Cell 17 Lymphoma, Non-Hodgkin 14 Carcinoma, Non-Small-Cell Lung 13 Prostatic Neoplasms 12 Vomiting 11 Neoplasm Metastasis 8 Leukemia, Myeloid, Acute 8 Precursor Cell Lymphoblastic Leukemia-Lymphoma 7 Nausea 7 Lymphoma, Large B-Cell, Diffuse 7 Lymphoma 7 Ovarian Neoplasms 6 Immunoglobulin Light-chain Amyloidosis 6 Hematologic Neoplasms 6 Parkinson Disease 4, Autosomal Dominant Lewy Body 5 Paraproteinemias 5 Lung Neoplasms 5 Leukemia 5 Small Cell Lung Carcinoma 4 Renal Insufficiency 4 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4 Plasmacytoma 4 Lymphoma, Follicular 4 Hematologic Diseases 4 Leukemia, Plasma Cell 3 Leukemia, Lymphocytic, Chronic, B-Cell 3 Breast Neoplasms 3

Interventions

enzalutamide 5 Prednisone 5 cabazitaxel 4 Docetaxel 3 Abiraterone Acetate 3 fludrocortisone acetate 1 Zuclomiphene 1 XRP6258 1 Standard of Care 1 Prednisolone 1 Midazolam 1 LY3023414 1 Injections 1 Hydrocortisone 1 Dexamethasone 1 Abituzumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Prostate Cancer Metastatic × Dexamethasone × Clear all

NCT06136624 2026-05-05

OMAHA-003

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡